Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 431-436

  Gibson, Gabrielle A ^a,b   Bauer, Seth R ^a   Neuner, Elizabeth A ^a   Bass, Stephanie N ^a   Lam, Simon W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BODY WEIGHT; CONTINUOUS RENAL REPLACEMENT THERAPY; CONVALESCENCE; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAM NEGATIVE SEPSIS; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; ACUTE KIDNEY INJURY; BACTEREMIA; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOGENICITY; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; COLISTIN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84957927698     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01414-15     Document Type: Article

References (23)

1. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org/10.1128/AAC.01733-10.
2. Shorr AF. 2009. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37:1463-1469. http://dx.doi.org/10.1097/CCM.0b013e31819ced02.
3. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. CDC, Atlanta, GA.
4. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:3783-3789. http://dx.doi.org/10.1128/AAC.00903-09.
5. Infectious Diseases Society of America. 2010. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081-1083. http://dx.doi.org/10.1086/652237.
6. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:473-477. http://dx.doi.org/10.1093/jac/dkl512.
7. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54:1117-1124. http://dx.doi.org/10.1128/AAC.01114-09.
8. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339. http://dx.doi.org/10.1378/chest.10-0463.
9. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30:143-151. http://dx.doi.org/10.1016/j.clinthera.2008.01.015.
10. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720-1726. http://dx.doi.org/10.1093/cid/cis286.
11. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35:194-199. http://dx.doi.org/10.1016/j.ijantimicag.2009.10.005.
12. Vicari G, Bauer SR, Neuner EA, Lam SW. 2013. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 56:398-404. http://dx.doi.org/10.1093/cid/cis909.
13. Devine BJ. 1974. Gentamicin therapy. Drug Intell Clin Pharm 8:650-655.
14. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
15. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 140:26-32. http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00008.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
17. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. 2001. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754-1758. http://dx.doi.org/10.1001/jama.286.14.1754.
18. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2005. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760-766. http://dx.doi.org/10.1128/AAC.49.2.760-766.2005.
19. Matzke GR, Frye RF. 1997. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 16:205-231.
20. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
21. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225-234. http://dx.doi.org/10.1016/S1473-3099(14)70850-3.
22. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093/cid/ciu213.
23. Gales AC, Reis AO, Jones RN. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183-190. http://dx.doi.org/10.1128/JCM.39.1.183-190.2001.